Biopharma | June 05, 2026
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
